Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults With Systemic Sclerosis
Conditions
Interventions
IgPro10
Placebo
Locations
77
United States
Mayo Clinic Arizona - Scottsdale
Scottsdale, Arizona, United States
Pacific Arthritis Care Center
Los Angeles, California, United States
University of California
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
University of Colorado
Aurora, Colorado, United States
Lombardi Cancer Center-Georgetown University
Washington D.C., District of Columbia, United States
Start Date
December 20, 2019
Primary Completion Date
September 16, 2020
Completion Date
September 16, 2020
Last Updated
November 17, 2020
NCT05270668
NCT05626751
NCT04986605
NCT04478994
NCT03198689
NCT02161406
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions